Crossmark

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review

Crossref DOI link: https://doi.org/10.1007/s40273-018-0631-8

Published Online: 2018-03-01

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Diamantopoulos, Alex https://orcid.org/0000-0002-5700-6265
Wright, Emily

Vlahopoulou, Katerina

Cornic, Laura

Schoof, Nils

Maher, Toby M.
Funding

Funding for this research was provided by:

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2018-03-01
More Information

Article History

First Online: 1 March 2018

Compliance with Ethical Standards

:

: This study was funded by Boehringer Ingelheim.

: KV, EW, LC and AD are employed by Symmetron Limited, which received funding from Boehringer Ingelheim for this project. AD has in the past received funding from Boehringer Ingelheim for the contribution to original research and similar articles. TM has received consulting fees from Symmetron Limited; industry-academic research funding from GlaxoSmithKline R&D and UCB; and consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, Dosa, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanofi-Aventis, Takeda and UCB. TM is supported by an NIHR Clinician Scientist Fellowship (NIHR Ref: CS-2013-13-017) and British Lung Foundation Chair in Respiratory Research (C17-3). NS is an employee of Boehringer Ingelheim.